Covid protection wanes months after second shot, booster needed: Studies

Last Updated on December 19, 2022 by Admin


Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.

Protective antibodies decreased continuously during the six months after the administration of the second dose of the vaccine, according to a study of about 5,000 Israeli health workers, published Wednesday in the New England Journal of Medicine. The levels fell first at a sharp pace and later at a more moderate one.

Researchers worldwide are trying to identify the critical threshold of antibodies needed to prevent infection, severe illness and death, said Gili Regev-Yochay, one of the authors of the study. Such studies will help assess risk levels for various groups and the measures needed to protect them, the researcher said.

Antibody levels were found to be lower in older people than in younger, and in immunosuppressed individuals compared to the healthy population, according to the study from Sheba Medical Center in Ramat Gan. Men’s antibody counts were lower than those of women both at their peak and at the end of the study.

The research shows why there are breakthrough infections in individuals who have had two vaccine doses, Regev-Yochay said in an online press briefing. The U.S., which has restricted its booster recommendation to older people and other vulnerable groups, will likely follow Israel’s decision to offer a third dose to the entire population, she said.

“I would be more than surprised if we are not going to start to see a lot of breakthrough infections in the United States,” among those who have received just two doses, Regev-Yochay said.

ALSO READ: Coronavirus LIVE: India records 22,431 cases, 318 deaths in the last 24 hrs

The Israel findings were bolstered by a second real-world study from Qatar, published in the same journal, that found the efficacy of the Pfizer-BioNTech shot faded over a similar time period. Protection fell from 77.5% during the first month after the second dose to 20% in months five to seven after the second dose.

Still, the research found, prevention of severe and fatal infections remained strong throughout the study period, reaching 96% in the first two months after the second dose and persisting at roughly this level for six months.

Consistent data

“The data is consistent,” said Laith Abu-Raddad, a coauthor of the paper who studies infectious disease epidemiology at Weill Cornell Medicine-Qatar. “Protection against hospitalization and death is really strong and more durable than protection against infection.” Giving a third booster shot helps optimize the protection from the vaccine, he said.

Two other studies from Israel published in the journal also followed up on early reports of heart inflammation following Cases of inflammation, called myocarditis, although rare, increased after the receipt of the vaccine, according to one study by the Israeli Health Ministry and Hadassah Hebrew University Medical Center, particularly after the second dose among young male recipients. While cases were usually mild, one was fatal.

Another study by the Clalit Health Services, the largest health-care system in the country, found that the estimated incidence of myocarditis was 2.13 cases per 100,000 persons. The highest incidence was among male patients between the ages of 16 and 29. Most of the cases were mild or moderate.

mail Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Source link